FLAURA2: Exploratory Overall Survival (OS) Analysis in Patients (Pts) with Poorer Prognostic Factors Treated with Osimertinib (Osi) ± Platinum-Pemetrexed Chemotherapy (CTx) as First-Line (1L) Treatment (Tx) for EGFR-Mutated (EGFRm) Advanced NSCLC

Lead presenter Passi Jaane, MD, PhD presents key data on the FLAURA2 trial presented at ESMO 2025.

Sailaja Kamaraju, MD

Barry W. Goy, MD

Barry W. Goy, MD, is a physician in the Department of Radiation Oncology at Kaiser Permanente.

Latest:

Dr Goy on Unclear Survival Benefit With Neoadjuvant ADT Plus EBRT in Intermediate-Risk Prostate Cancer

Barry W. Goy, MD, discusses 15-year survival outcomes with neoadjuvant androgen deprivation therapy plus EBRT in intermediate-risk prostate cancer.

Kathleen O’Brien

Latest:

The Desire to Always Do More

Jaffer A. Ajani, MD, has an unyielding drive that has resulted in breakthroughs in a deadly, but often overlooked, disease.

Marlana M. Orloff, MD

Marlana M. Orloff, MD, is an associate professor at Jefferson University and physician in the Department of Medical Oncology at Sidney Kimmel Cancer Center.

Latest:

Dr Orloff on OS Outcomes With Darovasertib Plus Crizotinib in Metastatic Uveal Melanoma

Marlana Orloff, MD, discusses efficacy findings with darovasertib plus crizotinib in metastatic uveal melanoma that were seen in the OptimUM-01 trial.

Annie Im, MD, FASCO

Latest:

Dr Annie Im: How to Treat Acute Myeloid Leukemia in 2024

Annie Im, MD, FASCO, University of Pittsburgh/UPMC Hillman Cancer Center, discusses the various modern approaches for the treatment of patients with acute myeloid leukemia.

Haeseong Park, MD, MPH

Latest:

Dr Park on the Combo of Epacadostat and Chemoradiation in Advanced Rectal Cancer

Haeseong Park, MD, MPH, discusses the rationale for combining epacadostat with preoperative chemoradiation in locally advanced rectal cancer.

Gordana Vunjak-Novakovic, PhD, BS, MS

Latest:

Dr. Vunjak-Novakovic on the Clinical Need for Personalizing Cancer Care

Gordana Vunjak-Novakovic, PhD, BS, MS, discusses the clinical need for personalizing cancer care.

Antonio Martin Jimenez Jimenez, MD

Latest:

Dr Jimenez Jimenez on the Clinical Implications of the ACCESS Trial in Hematological Malignancies

Antonio Martin Jimenez Jimenez, MD, discusses the clinical implications of PBSC from HLA-MMUD and PTCy for GVHD prophylaxis in hematological malignancies.

Debra L. Richardson, MD, FACS, FACOG

Latest:

Long-Term Safety and Efficacy of Selinexor Maintenance Treatment in Patients With TP53 Wild-Type Advanced or Recurrent Endometrial Cancer: Follow-up Subgroup Analysis of the ENGOT-EN5/GOG-3055/SIENDO Study

Dr. Debra Richardson presents a subgroup analysis of the SIENDO trial, showing that selinexor maintenance therapy significantly improves progression-free survival and delays subsequent treatment in patients with TP53 wild-type advanced or recurrent endometrial cancer, with manageable safety and potential long-term benefit.